Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ajmalicine (also known as raubasine) is a monoterpenoid indole alkaloid isolated from several Rauvolfia and Catharanthus species. It is a small molecule drug primarily used as an antihypertensive agent for the treatment of high blood pressure and has also been applied in the management of circulatory disorders such as cerebrovascular and peripheral vascular diseases. Ajmalicine acts mainly as a selective alpha1-adrenergic receptor antagonist (alpha1-adrenoceptor antagonist), leading to vasodilation and improved cerebral blood flow. It has also demonstrated anticonvulsant properties in animal studies. In some formulations (notably combinations with almitrine), it has been used to enhance cerebral oxygenation and glucose uptake in elderly patients with cognitive impairment or other neurosensory deficits[1][2][3][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ajmalicine.